Regeneron Pharmaceuticals EBITDA 2010-2024 | REGN
- Regeneron Pharmaceuticals 2024 EBITDA was 4.474B, a 0.12% increase from 2023.
- Regeneron Pharmaceuticals 2023 EBITDA was 4.468B, a 12.05% decline from 2022.
- Regeneron Pharmaceuticals 2022 EBITDA was 5.08B, a 44.98% decline from 2021.
EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.